NeuroMetrix, Inc. (NASDAQ:NURO) Short Interest Down 62.5% in March

NeuroMetrix, Inc. (NASDAQ:NURO) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 600 shares, a drop of 62.5% from the March 15th total of 1,600 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 11,500 shares, the short-interest ratio is currently 0.1 days.

NeuroMetrix Stock Down 0.9 %

NURO traded down $0.04 during trading on Wednesday, reaching $4.34. The company had a trading volume of 663 shares, compared to its average volume of 16,991. The business has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $4.18. The stock has a market cap of $8.94 million, a P/E ratio of -0.95 and a beta of 1.82. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroMetrix stock. GTS Securities LLC purchased a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 22,759 shares of the medical device company’s stock, valued at approximately $90,000. GTS Securities LLC owned 1.12% of NeuroMetrix at the end of the most recent quarter. Institutional investors and hedge funds own 19.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on NeuroMetrix in a report on Sunday. They set a “sell” rating for the company.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.